Keros Therapeutics, Inc. Common Stock
KROSKeros Therapeutics, Inc. (KROS) is a biotechnology company focused on the development of novel therapeutics aimed at addressing hematologic and neurodegenerative disorders. The company specializes in targeting cytokine pathways to develop treatments that modulate hematopoiesis and neurobiology, with an emphasis on improving patient outcomes through innovative drug discovery and development.
Company News
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in l...
Keros Therapeutics presented Phase 1 clinical trial data for rinvatercept (KER-065), a ligand trap designed to inhibit myostatin and activin A for treating neuromuscular diseases. The drug demonstrated good tolerability with no serious adverse events, increased muscle mass, decreased fat mass, and increased bone mineral density. Proteomic analysi...
Keros Therapeutics completed its cash tender offer to repurchase up to 10,950,165 shares of common stock at $17.75 per share, totaling approximately $194.4 million. More shares were tendered than the company could purchase, resulting in a pro-rata allocation.
Keros Therapeutics completed a cash tender offer to repurchase up to 10,950,165 shares of its common stock at $17.75 per share, totaling approximately $194.4 million. More shares were tendered than the target, so shares will be accepted on a pro rata basis.
Over 25 pharmaceutical companies are developing TGF-β inhibitor drugs targeting oncology and fibrosis treatments, with promising pipeline therapies showing potential for addressing significant unmet medical needs.
